Mandeep Kaur

Mandeep Kaur

Auto-generated profile, based on publicly available information

Mandeep Kaur

Cardeza Foundation for Hematologic Research, Department of Medicine, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2023 in Basic and Clinical Neuroscience Journal
Verified
Journal Article
Open access
PDF file
TGTulika Gupta
Tulika Gupta
MKMandeep Kaur
Mandeep Kaur
DSDevendra Shekhawat
Devendra Shekhawat
RARitu Aggarwal
Ritu Aggarwal
NNNeha Nanda
Neha Nanda
DSDaisy Sahni
Daisy Sahni
Introduction: Emerging evidence has shown that the glucagon-like peptide-1 (GLP-1) agonist can be used to treat Alzheimer disease; however, knowledge of its neural targets is limited. To understand the neural substrates of GLP-1, we have done whole brain mapping for GLP-1 and its receptor (GLP-1R), in 30 human brains. Methods: GLP-1 expression was studied by immuno-histochemistry and confirmed by the western blot method. The GLP-1R gene expression was studied by reverse transcription polymerase chain reaction. Results: GLP-1 expression was observed in most of the cortical areas (maximum in frontal, prefrontal and parietal cortex), diencephalon, and brainstem, but not in the cerebellum. Protein expression studies validated these results. The highest expression of GLP-1R was found in the frontal cortex. The orbitofrontal cortex and cerebellum had negligible expression. Hippocampus demonstrated a significant presence of GLP-1R but patchy immunoreactivity to GLP-1. GLP-1R presence in most of the human cortical regions and absence in the cerebellum is the major deviation from the animal brain. Sites that might be of interest in Alzheimer have been identified. GLP-1 demonstrated an age-related decline in most of the areas after the fifth decade. At 60 years, GLP-1 was not found in any of the cortical areas except in the prefrontal cortex; however, it was present in the sub-cortical areas. Conclusion: Age-related profiling of GLP-1 in various brain areas has been analyzed, which can have an important bearing on understanding Alzheimer disease. This study provides a detailed description of GLP-1 and an brain mapping for the first time and may lead to novel treatment options targeting the GLP-1 receptors.

1 April 1998 in Molecular and Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
MKM. Kaur
M. Kaur
DKD. Kaul
D. Kaul
RSR.C. Sobti
R.C. Sobti

1 September 2023 in Basic and Clinical Neuroscience Journal
Verified
Journal Article
Open access
PDF file
MKMandeep Kaur
Mandeep Kaur
TGTulika Gupta
Tulika Gupta
MGMili Gupta
Mili Gupta
NSNavneet Singla
Navneet Singla
PKParampreet S. Kharbanda
Parampreet S. Kharbanda
SGSunil Kumar Gupta
Sunil Kumar Gupta
Introduction: About 30% of patients with epilepsy do not respond to anti-epileptic drugs, leading to refractory seizures. The pathogenesis of drug-resistance in mesial temporal lobe epilepsy (MTLE) is not completely understood. Increased activity of drug-efflux transporters might be involved, resulting in subclinical concentrations of the drug at the target site. The major drug-efflux transporters are permeability glycoprotein (P-gp) and multidrug-resistance associated protein-1 (MRP-1). The major drawback so far is the expressional analysis of transporters in equal numbers of drug-resistant epileptic tissue and age-matched non-epileptic tissue. Methods: We have studied P-gp and MRP-1 drug-efflux transporters in the sclerotic hippocampal tissues resected from the epilepsy surgery patients (n=15) and compared their expression profile with the tissues resected from non-epileptic autopsy cases (n=15). Results: Statistically significant over expression of both P-gp (P<0.0001) and MRP-1 (P=0.01) at gene and protein levels were found in the MTLE cases. The fold change of P-gp was more pronounced than MRP-1. Immunohistochemistry of the patient group showed increased immunoreactivity of P-gp at blood-brain barrier and increased reactivity of MRP-1 in the parenchyma. The results were confirmed by confocal immunofluorescence microscopy. Conclusion: Our results suggested that P-gp in association with MRP-1 might be responsible for the multi-drug resistance in epilepsy. P-gp and MRP-1 could be important determinants of bio availability and tissue distribution of anti-epileptic drugs in the brain which can pharmacologically inhibited to achieve optimal drug penetration to target site.

16 February 2026 in Blood Vessels, Thrombosis & Hemostasis
Verified
Journal Article
Open access
MKMandeep Kaur
Mandeep Kaur
MGMalvika Gupta
Malvika Gupta
SGSowmya Shree Gopal
Sowmya Shree Gopal
CWCharles E. Wade
Charles E. Wade
JCJessica C. Cardenas
Jessica C. Cardenas
ASAmit K. Srivastava
Amit K. Srivastava
• Female-derived PEVs from resting platelets offer superior endothelial barrier protection vs male-derived and stored-platelet PEVs.